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ABSTRACT 
Genome wide association studies (GWAS) have identified multiple risk loci for testicular germ cell 
tumour (TGCT), revealing a polygenic model of disease susceptibility strongly influenced by 
common variation. To identify additional SNPs associated with TGCT we conducted a multistage 
GWAS with a combined dataset of >25,000 individuals (6,059 cases and 19,094 controls). We 
identified new risk loci for TGCT at 3q23 (rs11705932, TFDP2, P = 1.5 x 10
-9
), 11q14.1 (rs7107174, 
GAB2, P = 9.7 x 10
-11
), 16p13.13 (rs4561483, GSPT1, P = 1.6 x 10
-8
) and 16q24.2 (rs55637647, 
ZFPM1, P = 3.4 x 10
-9
). We additionally present detailed functional analysis of these loci, 
identifying a statistically significant relationship between rs4561483 risk genotype and increased 
GSPT1 expression in TGCT patient samples. These findings provide additional support for a 
polygenic model of TGCT risk and further insight into the biological basis of disease development. 
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INTRODUCTION  
 
Testicular germ cell tumour (TGCT) is the most common cancer in men aged 15-45 years, with over 
18,000 new cases diagnosed annually in Europe
1,2
. The incidence of TGCT has approximately doubled 
over the last four decades in Western Europe
3
, which implicates environmental or lifestyle factors as 
risk determinants. However to date no exogenous associations have been robustly validated
4
.  
Family and twin studies support a strong genetic basis to TGCT susceptibility
5,6
, with brothers of 
cases having an eight-fold increased risk of TGCT
7
. Direct evidence for inherited genetic susceptibility 
to TGCT has come from recent genome-wide association studies (GWAS), which have identified a 
number of independent loci influencing TGCT risk
8-17
. The associations identified by GWAS have 
provided novel insights into the development of TGCT, highlighting the role of genes involved in 
KIT/KITLG signalling, telomerase function, microtubule assembly and DNA damage repair 
18
.  
 
The over-representation of association signals in GWAS after accounting for known risk loci supports 
the existence of additional risk loci for TGCT. To identify new risk variants for TGCT we have 
performed a GWAS meta-analysis, genome wide imputation and large scale replication genotyping. 
Our combined data-set comprises over 25,000 individuals and >8 million SNPs, the largest study of 
its kind to date for TGCT. We report the identification of four new risk loci for TGCT. 
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RESULTS 
 
Association analyses 
We adopted a three-stage design, incorporating: GWAS discovery, custom array follow up and 
replication genotyping (Figure 1). Genome-wide discovery (stage 1) was performed in 986 TGCT 
cases and 4,946 controls for 307,291 SNPs, as previously described
10,16
. The most strongly associated 
SNPs from stage 1 were included on a custom consortia array (iCOGs) and follow up genotyping 
(stage 2) was conducted in an additional 1,064 cases of TGCT and 10,082 controls, as previously 
described
12,19
. Meta-analysis was then conducted on 57,066 SNPs overlapping between stages 1 and 
2. To achieve dense genome-wide coverage we retrospectively imputed unobserved genotypes 
(stage 1a) using our discovery GWAS dataset and the 1000 genomes project reference panel. Results 
from meta-analysis and imputation were filtered to identify 20 SNPs at 12 loci with promising signs 
of association based on the following criteria: i) P < 5.0 x 10
-4
, ii) SNPs mapping to distant loci not 
previously associated with TGCT risk, iii) in-silico look-up in a Scandinavian GWAS dataset comprising 
1,326 cases and 6,687 controls genotyped using Human OmniExpressExome-8v1 Illumina arrays  (P < 
0.1) 
17
, iv) consistent odds ratio (OR) effect sizes and allelic frequencies across all datasets. For these 
12 loci we conducted a replication study (stage 3), genotyping an additional 4,009 TGCT cases and 
4,066 controls. Genotyping was successful for SNPs at 10 of the 12 loci. All case and control samples 
were from the UK and formed unique sets, with no individuals overlapping between stages.  
 
We tested association between each SNP and TGCT risk at each stage using the 1 d.f. trend test, with 
data from stages 1 and 2 being adjusted for six principal components. Inflation in the test statistics 
was ŽďƐĞƌǀĞĚĂƚŽŶůǇŵŽĚĞƐƚůĞǀĞůƐ ?ʄA?1.05, ʄ1000 < 1.02 across all stages). A combined fixed-effects 
meta-analysis was performed for SNP data across all stages, for the 10 successfully genotyped loci. In 
the combined meta-analysis SNPs at four novel loci attained genome-wide significance (P < 5.0 x 10
-
8
) (table 1, figure 2). Firstly, rs11705932 (OR = 1.18, CI = 1.09-1.28, P = 1.5 x 10
-9
) which lies within a 
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240kb region of linkage disequilibrium (LD) at 3q23, containing genes TFDP2 and ATP1B3. Secondly, 
rs7107174 (OR = 1.26, CI = 1.16-1.37, P = 9.7 x 10
-11
) which maps to intron 1 of GAB2 (11q14.1), in a 
227Kb region of LD to which USP35 also localises. Thirdly rs4561483 (OR = 1.09, 95% CI = 1.02-1.16, 
P = 1.6 x 10
-8
) intronic to BCAR4 (16p13.13) within a 145kb LD block also containing RSL1D1, GSPT1 
and TNFRSF17. Finally, rs55637647 (OR = 1.17, CI = 1.09-1.24, P = 3.4 x 10
-9
) mapping within intron 1 
of ZFPM1 (16q24.2), within a 40Kb LD block.  
We examined for evidence of genotype specific effect for rs11705932, rs7107174, rs4561483 and 
rs55637647, however no significant departure from a log-additive model was seen. We additionally 
tested for interaction between rs11705932, rs7107174, rs4561483 and rs55637647 and SNPs at 
previously identified risk loci for TGCT (Supplementary table 2). Some evidence of interaction 
between rs11705932 and previously reported SNP rs12699477 (at 7p22.3) was shown (P = 0.003), 
albeit non-significant after correcting for 84 tests.   
 
Functional analysis of the four new TGCT SNPs  
To gain insight into the biological basis of associations at rs11705932, rs7107174, rs4561483 and 
rs55637647, we conducted expression quantitative trait loci (eQTL) analysis using RNA-seq 
expression and Affymetrix 6.0 SNP / exome sequencing data on 150 TGCT patients, which is 
publically available through the cancer genome atlas (http://cancergenome.nih.gov/). Where data 
for our sentinel SNP was not available we analysed data for the best two proxy SNPs (defined as 
those with the highest r
2
 correlation) for which data was available, namely: 3q23 (sentinel SNP 
rs11705932), 11q14.1 (rs2450140, r
2
= 0.88 and rs11237477, r
2
= 0.86), 16p13.13 (rs2075158, r
2
= 0.78 
and rs2018199, r
2
= 0.79) and 16q24.2 (rs3859027, r
2
= 0.91 and rs12597021, r
2
= 0.87). Each of the 
nine genes (ATP1B3, BCAR4, GAB2, GSPT1, RSL1D1, TFDP2, TNFRSF17, USP35 and ZFPM1) within the 
LD blocks at the four new risk loci were tested for evidence of an eQTL. No significant associations 
were identified at 11q14.1, 3q23 or 16q24.2. However a statistically significant association was 
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found at 16p13.13, between genotype and expression of GSPT1 (proxy SNPs rs2075158 P = 5.1 x 10
-
4
, rs2018199 P = 5.9 x 10
-4
), which remained significant after correction for multiple testing 
(Supplementary table 1). Both SNPs rs2075158 and rs2018199 can be considered good proxy 
markers, having high r
2
 correlation with and closely comparable minor allelic frequencies to, the 
sentinel SNP.  Homozygosity for the risk allele at rs2075158 was associated a with 35% increase in 
GSPT1 expression compared to the reference homozygote genotype (Supplementary figure 1).  
 
We used HaploReg
20
 and Roadmap Epigenome Mapping Consortium data on enhancer elements to 
examine whether rs11705932, rs7107174, rs4561483 and rs55637647 or their proxies (i.e. r
2
 > 0.8 in 
1000 Genomes CEU reference panel) lie at putative transcription factor binding/enhancer elements.  
In addition, we analysed GERP (Genomic Evolutionary Rate Profiling) scores to asses sequence 
conservation (Supplementary data). At 11q14.1, which contains GAB2, there is evidence of strong 
evolutionary conservation, with 21 correlated SNPs having GERP score > 2.0, the strongest of which 
is SNP rs2511156 which is in almost perfect LD with the sentinel SNP. In addition multiple correlated 
SNPs at 11q14.1 are predicted to be in strong enhancer regions, with four SNPs located within DNase 
hypersensitivity sites in the TGCT specific cell line NT2-D1. Furthermore, 10 correlated SNPs at 
11q14.1 alter the binding motif of embryonic transcription factor NANOG, a pluripotency factor 
strongly implicated in TGCT development
21
. At 16q24.2 the sentinel SNP rs55637647 is conserved 
and EGR1 binding, an early growth response transcription factor linked to infertility and differential 
expression in germ cell tumours
22,23
, was also reported within the LD block. No evidence of 
evolutionary conservation was seen for any SNPs at either 3q23 or 16p13.13 risk loci; however both 
loci feature SNPs mapping to predicted enhancers. In addition the significantly associated eQTL SNP 
at 16p13.13 (rs2075158) lies within a predicted strong active promoter site.  Both 3q23 and 
16p13.13 risk loci also have SNPs shown to alter the binding motif of SOX family transcription 
factors, which regulate germ cell development and sex determination.  In addition the protein 
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STAT3, which is critical for embryonic development and is expressed in the developing spermatids of 
adult testis
24
, binds to the locus at 3q23. 
 
Finally, using matched tumour/normal exome sequencing data from our recent study of 42 UK TGCT 
patients 
25
, we analysed somatic mutational events occurring in genes ATP1B3, BCAR4, GAB2, GSPT1, 
RSL1D1, TFDP2, TNFRSF17, USP35 and ZFPM1. The only recurring event, seen in >5% of tumours was 
a copy number deletion encompassing GAB2 and USP35 at 11q14.1 found in 7% of tumours. These 
deletions were large, spanning up to 55Mb.  
 
Pathway analysis 
We performed gene set enrichment analysis to determine whether any of the genes mapping to our 
four newly identified loci reside in pathways already enriched with TGCT SNPs. Using the i-
GSEA4GWAS algorithm 
26
 on stage 1 data, a total 31 pathways showed enrichment in analysis of 
genome-wide association data for TGCT (FDR<0.1; Supplementary table 3). Five pathways were of 
note: those involved in sex determination, centrosome cycle, apoptosis, KIT/KITLG signalling and 
DNA damage repair, further substantiating existing evidence linking these gene sets to TGCT 
17,18,27
. 
Focusing on these five pathways, genes at three of the new loci feature (see Supplementary Figure 
2). The first related pathway involves GAB2 at 11q14.1, a member of the GRB2-associated binding 
protein (GAB) gene family, which associates with KIT forming a critical part of the KIT/KITLG 
signalling cascade
28
.  The second related gene is ZFPM1 at 16q24.2, linked to sex determination, with 
ZFPM1 being shown to specify germ cell differentiation as sperm rather than oocytes in 
Caenorhabditis elegans 
29
. Both ZPFM1 and its paralogue ZPFM2 regulate the activity of GATA family 
of transcription factors, which are abundantly expressed from the onset of human gonadal 
development and found in multiple cell lineages of the testis
30,31
. The third related gene is GSPT1 at 
16p13.13, which is a documented determinant of apoptosis
32
. 
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Personalised risk profiling 
The odds ratio (OR) effect sizes of TGCT SNPs have been among the highest reported in GWAS of any 
cancer type
33
, hence suggesting a potential clinical utility for personalised risk profiling. To assess 
this potential we constructed polygenic risk scores (PRS) for TGCT, considering the combined effect 
of all risk SNPs modelled under a log-normal relative risk distribution, as implemented for other 
cancer types
34-36
. Using this approach for the four new risk loci, together with all existing risk SNPs 
(Supplementary Table 2), the men in the top 1% of genetic risk had a 10.4-fold relative and 5.2% 
lifetime risk of TGCT (Figure 3). 
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DISCUSSION 
 
Here we have genotyped the largest number of TGCT cases to date, identifying four novel TGCT 
susceptibility loci at 3q34, 11q14.1, 16p13.13 and 16q24.2. We additionally performed TGCT cell 
type specific eQTL analysis of these loci, identifying a possible cis-regulatory effect on GSPT1 
expression at 16p13.13. Aside from the detailed functional work undertaken by Bond et al. exploring 
the mechanism underlying the signal at 12q21
37
, this is the first statistically significant eQTL 
identified for TGCT.  
 
Of the four new loci, the functional mechanism at 16p13.13 is most tangible, with expression of 
GSPT1 (G1- TO S-PHASE TRANSITION 1) found to be up-regulated in risk allele carriers. GSPT1 is a 
proto-oncogene essential for the G1-to-S phase cell cycle transition and regulates mammalian cell 
growth
38,39
. Perhaps not surprisingly, GSPT1 has been shown to be up-regulated in multiple tumour 
types, including cancers of the stomach, prostate and breast
40-42
.  Furthermore, inherited variants in 
GSPT1 have been reported to confer elevated risk of gastric cancer
41
. As the sample size of available 
RNA-seq expression data we used is relatively modest (n=150), analysis of this effect in a larger 
dataset would be of significant interest. GSPT1 is also cited as a potential target for anticancer 
therapy
40
, due to its role regulating cell cycle progression, a process  effectively targeted for various 
existing drug classes such as mTOR pathway inhibitors.  
 
At the second locus (11q14.1) there are competing functional hypotheses, with strong TGCT cell-
type specific evidence being observed to suggest an influence on gene expression. Of the two genes 
in LD at 11q14.1 a plausible candidate is GAB2 (GRB2-associated binding protein 2), which encodes a 
docking protein that is important in signal transduction from tyrosine kinases and is bound by GRB2.  
GAB2 has been demonstrated to act as a proto-oncogene in breast, colorectal and ovarian cancers as 
well as melanoma
43,44
, and has been shown to be therapeutically targetable by imatinib and 
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dasatinib
45
. Our eQTL analysis did not demonstrate a link between rs7107174 and GAB2 expression, 
although this failure may be due to the imperfect correlation between the true functional SNP and 
proxy markers available. Alternatively other functional mechanisms may underpin the association; of 
particular note, a missense variant (rs2510044) responsible for the P236M polymorphism in USP35 
(ubiquitin specific peptidase 35) is in perfect LD with our sentinel SNP. P236M is predicted to be 
pathogenic using the CONDEL algorithm
46,47
. In our somatic datasets a recurring deletion 
encompassing both GAB2 and USP35 was found in 7% of tumours, however due to the large scale of 
these deletions there is no evidence to suggest they specifically relates to the 11q14.1 locus. 
 
At the third locus (16q24.2) ZFPM1 (ZINC FINGER PROTEIN, MULTITYPE 1, also known as FOG, Friend 
of GATA1) is the only gene in LD with the sentinel SNP. While we cannot exclude a regulatory effect 
outside of the LD block, ZFPM1 provides an attractive functional basis for association being a 
regulator of the transcription factor GATA1. ZFPM1 is expressed in human Sertoli cells, first in the 
late fetal stages and then throughout postnatal testicular development
48
. GATA transcription factors 
were first implicated in carcinogenesis ŽǀĞƌƚǁŽĚĞĐĂĚĞƐĂŐŽ ?ĂŶĚƚŚĞŝƌƌŽůĞŝŶǀĂƌŝŽƵƐůĞƵŬĂĞŵŝĂ ?ƐŝƐ
now well established
49
. Additionally GATA1 directly contributes to the silencing of KIT, a pathway 
which is strongly implicated in both germline and somatic studies of TGCT
49,50
. The last remaining 
locus (3q23) contains genes TFDP2 (Transcription Factor DP2) and ATP1B3 (ATPase, Na+/K+ 
Transporting, Beta 3 Polypeptide). While eQTL analysis was not able to establish a link between 
rs11705932 genotype and expression of either gene, TFDP2 is a plausible functional candidate, as 
expression of this gene is itself regulated by binding of GATA1
51
. In this study we therefore implicate 
FOG/GATA1 genes in TGCT susceptibility for the first time, highlighting a network of interlinked 
oncogenic pathways. 
 
These four new loci provide further biological insight into this tumour, as well suggesting a possible 
new target for TGCT therapy, with reduced toxicity potential compared to current treatment 
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options. In addition these loci add additional insights into the pathways relevant to TGCT 
susceptibility, in particular to those related to sex determination, apoptosis and KIT/KITLG signalling. 
Our genome-wide pathway analysis also highlighted the centrosome cycle and DNA damage repair 
pathways, consistent with previous studies. More extensive pathway mapping of TGCT risk loci 
would be informative, in particular to explore pathways related to telomerase function and male 
germ cell development. Both these later two pathways are functionally related to genes in LD with 
existing TGCT risk loci (see Supplementary Table 2), however they were not identified as significant 
by the iGSEA4GWAS algorithm, possibly due to the imperfect nature of pathway definitions.    
 
Our four new risk loci, together with the previously known risk SNPs for TGCT, collectively explain 
19% of the sibling risk of TGCT. We constructed a PRS model to assess the clinical utility of TGCT risk 
SNPs, which demonstrated marked power in terms of risk discrimination, with men in the top 1% of 
genetic risk exhibiting a >10-fold increased risk of the disease. However consideration of lifetime risk 
highlights the rare nature of TGCT, with high relative risks translating into only modest absolute risk. 
Hence the current clinical utility of PRS-based risk stratification may be limited in terms of 
population level screening; however targeted models (such as screening individuals at already 
elevated baseline risk) could offer more immediate benefit. In addition, discovery of additional risk 
SNPs may also improve clinical utility and recent population and genomic analyses of heritability 
have shown that: (i) TGCT is a highly heritable cancer (heritability ~48%),  and (ii) a significant 
proportion of the heritability is likely to reside within common SNPs 
52
. It is therefore likely that 
additional GWAS and meta-analyses will indeed lead to the identification of further risk SNPs for 
TGCT.  
 
In conclusion, by performing large-scale genotyping we have identified four novel susceptibility loci 
for TGCT. Our functional analysis has identified a link between risk genotype at 16p13.13 and 
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regulation of GSPT1 expression, as well as highlighting plausible oncogenic candidates across the 
remaining loci.  
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METHODS 
 
Sample description 
Cases with a diagnosis of TGCT were ascertained from two studies (1) a UK study of familial testicular 
cancer and (2) a systematic collection of UK collection of TGCT cases. Case recruitment was via the 
UK Testicular Cancer Collaboration, a group of oncologists and surgeons treating TGCT in the UK 
(Supplementary note 1). The majority of cases included in stage 3 were sporadic (3,941 sporadic vs 
68 familial), hence sub-analysis of sporadic versus familial effect size was not possible. The studies 
were co-ordinated at the Institute of Cancer Research (ICR). Samples and information were obtained 
with full informed consent and  Medical Research and Ethics Committee approval (MREC02/06/66 
and 06/MRE06/41).   
Controls for the stage 1 GWAS were from two sources within the UK: 2,482 controls were from the 
1958 Birth Cohort (1958BC), and 2,587 controls were identified through the UK National Blood 
Service (NBS) and were genotyped as part of the Wellcome Trust Case Control Consortium. Controls 
for the stage 2 genotyping were from three sources within the UK. 814 cancer-free, male controls 
age <65 from the UK were recruited through the UK Genetic Prostate Cancer Study (UKGPCS), a 
study conducted through the Royal Marsden NHS Foundation Trust.  7,871 cancer-free controls 
(1,244 male) were recruited via GP practices in East Anglia (2003-2009) as part of SEARCH (Study of 
Epidemiology & Risk Factors in Cancer).  1,397 cancer-free female controls from across the UK were 
recruited via the BBCS (British Breast Cancer Study). Controls for stage 3 replication genotyping were 
taken from two studies, the national study of colorectal cancer genetics (NSCCG)
53
 and GEnetic Lung 
CAncer Predisposition Study (GELCAPS)
54
. NSCCG and GELCAP controls were partners of cancer 
patients with no personal history of cancer at time of ascertainment. 
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Genotyping 
Genotyping for stages 1 and 2 was performed as previously reported
10,12,16
. In brief, stage 1 cases 
were genotyped on the Illumina HumanCNV370-Duo bead array (Ilumina, San Diego, CA, USA) and 
controls were genotyped on the Illumina Infinium 1.2M array. We used data on 314,861 SNPs that 
were successfully genotyped on both arrays. Stage 2 genotyping was conducted using a custom 
Illumina Infinium array (iCOGS array) comprising 211,155 SNPs selected across multiple consortia 
within the COGS (Collaborative Oncological Gene-environment Study), as previously described
12,19
. 
SNPs attaining an Illumina design score of A? ? ? ?ǁĞƌĞŝŶĐůƵĚĞĚŽŶƚŚĞĂƌƌĂǇ ?ƚŽƚĂůŽĨ ? ? ? ? ? ?^EWƐ
overlapped with our stage 1 dataset and were included in the meta-analysis. For stage 3 genotyping 
we designed KASPar allele-specific SNV primers
55
, genotyping 20 SNPs across the 10 loci. Genotyping 
was conducted by external laboratory LGC Limited, Unit 1-2 Trident Industrial Estate, Pindar Road, 
Hoddesdon, UK.  
  
Quality Control 
Stage 1 data was filtered as follows, we excluded individuals: i) with low call rate (<95%), ii) with 
abnormal autosomal heterozygosity or iii) with >10% non-European ancestry (based on multi-
dimensional scaling). We filtered out all SNPs with: (i) minor allele frequency <1%, (ii) a call rate of 
<95% in cases or controls or (iii) minor allele frequency of 1 ?5% and a call rate of <99% or (iv) 
deviation from Hardy-Weinberg equilibrium (10
-12
 in controls and 10
-5 
in cases). The final number of 
SNPs passing quality control filters was 307,291. Stage 2 data filtering was conducted on the full SNP 
set of 211,155 SNPs on the iCOGS array, with QC exclusions applied as follows to subjects: i) subjects 
with overall call rate <95% or deficit/excess of heterozygosity (P<10
-6
), ii) using identity-by-state 
ĞƐƚŝŵĂƚĞƐďĂƐĞĚŽŶ ? ? ? ? ? ?ƵŶĐŽƌƌĞůĂƚĞĚ^EWƐ ?ǁĞŝĚĞŶƚŝĨŝĞĚ “ĐƌǇƉƚŝĐ ?ĚƵƉůŝĐĂƚes and related 
samples and the sample with the lower call rate was excluded, iii) we identified ethnic outliers by 
 15 
 
multi-dimensional scaling by combining the iCOGS data with the three Hapmap2 populations using 
37,046 uncorrelated markers and removed individuals with >10% non-Western European ancestry. 
We included 1,064 cases and 10,082 controls in the final analysis. Stage 2 QC was applied to SNPs as 
follows: i) discrepant calls in more than 2% of duplicate samples across COGS consortia, ii) call rate 
<95%, MAF<1%, call rate <99% if MAF=1-5%, iii) deviation from Hardy-Weinberg (P<10
-5
 in controls, 
P <10
-12
 in cases). For stage 3, of the 20 SNPs designed 18 SNPs were successfully genotyped. From 
these 18 SNPs one SNP from each of the 10 loci was selected, based on the strongest signal of 
association. The average call rate across the 10 selected SNPs was 99.1% with all SNPs having a call 
rate of greater than 98.5%. All SNPs had a MAF greater than 1% and no SNP deviated from HWE at 
P<0.1. Hence all 10 SNPs passed pre-specified QC metrics. Call rates were assessed for individuals in 
stage 3, with 99.1% of individuals achieving a call rate of A?90% and 95.2% with call rate of 100%. A 
small number of individuals (n= 32, 0.4%) failed across all 10 SNPs and were excluded from the 
analysis. 
  
Statistical Analysis 
Statistical analysis for stages 1 and 2 was performed as previously reported
10,12,15,16
. In brief we 
tested for association between each SNP and TGCT risk at each stage using a 1 d.f. trend test, with 
data being adjusted for six principle components. Inflation in the test statistics was observed at only 
modest levels, with values before adjustment for principle components being: stage 1 inflation 
ĨĂĐƚŽƌ ?ʄ ?A? ? ? ? ? ?ĞƋƵŝǀĂůĞŶƚƚŽʄ
1000 
= 1.05) and stage 2 ʄA? ? ? ? ? ?ʄ1000=1.07). After adjustment for 
principle components: stage 1 ʄA? ? ? ? ? ?ʄ
1000 
= 1.00) and stage 2 ʄA? ? ? ? ? ?ʄ1000=1.02). In stage 3 the 10 
SNPs were tested for association with TGCT risk and per-allele ORs were estimated, using logistic 
regression with 1 .d.f, in-line with the stage 1 and stage 2 analyses. We obtained overall combined 
significance levels across all 3 stages using a fixed-effects meta-analysis, using a threshold of 
P<5.0x10
-8
 to denote genome-wide significance. For each novel locus we examined evidence of 
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departure from a log-additive (multiplicative) model, to assess any genotype specific effect. Using 
stage 3 data individual genotype data ORs were calculated for heterozygote (ORhet) and homozygote 
(ORhom) genotypes, which were compared to the per allele ORs. We tested for a difference in these 
1d.f. and 2d.f. logistic regression models to assess for evidence of deviation (P<0.05) from a log-
additive model. Using stage 1 data we examined for statistical interaction between the four new loci 
and the existing 21 TGCT predisposition loci by evaluating the effect of adding an interaction term to 
the regression model, adjusted for stage, using a likelihood ratio test (using a significance threshold 
of P < 5.95 x 10
-4
 to account for 84 tests). LD blocks were defined using the HapMap recombination 
rates (cM/Mb) and defined using the Oxford recombination hotspots
56
. Regional plots were 
generated using visPIG software
57
. Polygenic risk scores (PRS) were constructed using methods 
established by Pharoah et al
58
, based on a log-normal distribution LN (µ, V2) with mean µ and 
variance V2 (i.e. relative risk is normally distributed on a logarithmic scale). Lifetime TGCT risk was 
based on 2014 CRUK lifetime incidence rate of 0.5%
59
, multiplied by RR to give lifetime risk per 
percentile of the PRS. Competing mortality risk analysis was not conducted as over three quarters of 
TGCT cases present at ages 45 years and younger
59
, for whom cumulative mortality risk from all 
other causes is only 3.6%
60
. 
 
Imputation 
Genome wide imputation was performed using the genotyped data from Stage 1. The 1000 genomes 
phase 1 data (Sept-13 release) was used as a reference panel, with haplotypes pre-phased using 
SHAPEIT2
61
. Imputation was performed using IMPUTE2 software
62
 and association between imputed 
genotype and TGCT was tested using SNPTEST 
63
, under a frequentist model of association. QC was 
performed on the imputed SNPs; excluding those with INFO score < 0.8 and MAF < 0.01. 
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Functional Annotation 
We used data from the ENCODE project and HaploReg
20
 to investigate for evidence of transcriptional 
regulation at our identified locus, to assess whether: (i) the variant resides in a region in which 
modification of histone proteins is suggestive of enhancer and other regulatory activity (H3K4Me1 
and H3K27A histone modification) or promoter activity (H3K4Me3 histone modification), (ii) whether 
the variant lies in a region where the chromatin is hypersensitive to cutting by the DNase enzyme 
(suggestive of regulatory region), (iii) whether the variant lies in a region of binding of transcription 
factor proteins (as assayed by chromatin immunoprecipitation with antibodies specific to the 
transcription factor followed by sequencing of the precipitated DNA (ChIP-seq)), (iv) whether the 
variant affects a specific regulatory motif, as evaluated from position weighted matrices assembled 
from TRANSFAC, JASPAR and protein-binding microarray experiments. 
We investigated for evidence of association between the SNPs at our locus and changes in gene 
expression using publically available cancer genome atlas RNAseq and Affymetrix 6.0 SNP / exome 
sequencing data (http://cancergenome.nih.gov/). Where genotype data for our sentinel SNP was not 
available, we selected the top two closest proxy SNPs available in the combined SNP/exome 
datasets, based on highest r
2
 value. Associations between normalized RNA counts per-gene and 
genotype were quantified using the Kruskal ?Wallis trend test. A total of 18 tests were performed, 
hence a P-value threshold of 0.0028 was considered significant to correct for multiple testing.  
 
Pathway Analysis 
Pathway enrichment analysis was conducted using the Improved Gene Set Enrichment Analysis for 
Genome-wide Association Study (i-GSEA4GWASv1.1)
26
. Predefined biological pathways and 
processes including KEGG, reactome pathways and gene ontology gene sets (GO) were assessed for 
association with TGCT. SNPs within a +/- 5kb distance were mapped to genes and the maximum -
 18 
 
log(P value) of all the SNPs mapped to a gene was used to represent the gene, using SNP label 
permutation.  
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TABLES AND FIGURES LEGENDS 
Figure 1 - Study design, genotyping conducted over 3 stages, comprising non-overlapping samples 
from the UK. Imputation was performed on stage 1 GWAS data-set.  
 
Figure 2 A-D:  Regional plots of the four new TGCT loci. Shown by triangles ĂƌĞƚŚĞA?ůŽŐ10 association 
P values of genotyped SNPs, based on meta-analysis (three stage data for sentinel SNPs) and stages 
1/2 for all other SNPs. Shown by circles are imputed SNPs at each locus, which were imputed from 
the stage 1 dataset. The intensity of red shading indicates the strength of LD with the sentinel SNP 
(labeled). Also shown are the SNP build 37 coordinates in mega-bases (Mb), recombination rates in 
centi-morgans (cM) per mega-base (Mb) (in light blue) and the genes in the region (in dark blue). The 
zoomed in section displays the exact LD block for each SNP, with the sentinel SNP marked with a red 
triangle, any significant regulatory markers denoted with a red circle and the chromHMM prediction 
states coloured as per the legend. 
 
Figure 3 ʹ Population distribution of polygenic risk scores for TGCT, ordered from lowest to highest 
genetic risk (risk is relative to population median risk). Relative risk is plotted as a blue line, lifetime 
risk as red bars. Values are marked for individuals in the top 1% of highest genetic risk.
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SNP
1 
  
Chr. 
  
Allel
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2 
  
RAF
3 
Stage 1/1a  ? 
GWAS/Imputation 
Stage 2  ? iCOGs Stage 3 - Replication Combined 
OR
4
 (95% CI) Ptrend
5
 OR (95% CI) Ptrend OR (95% CI) Ptrend P meta
6
 P het
7 I
2
 
Het
8 
rs11705932 3 T/C 0.80 1.21 (1.07-1.37) 2.7x10
-3
 1.22 (1.08-1.38) 1.2x10
-3
 1.18 (1.09-1.28) 3.4x10
-5
 1.5x10
-9
 9.1x10
-1
 0 
rs147686985 3 G/C 0.02 1.80 (1.33-2.44) 2.6x10
-6
 - - 1.06 (0.84-1.33) 6.4x10
-1
 4.0x10
-1
 9.4x10
-3
 85 
rs13062518 3 T/C 0.43 1.21 (1.09-1.33) 2.6x10
-4
 1.14 (1.04-1.25) 6.1x10
-3
 1.06 (1.00-1.13) 6.3x10
-2
 9.6x10
-2
 1.0x10
-4 
91 
rs16873802 5 T/C 0.03 1.76 (1.33-2.32) 3.0x10
-5
 - - 1.06 (0.87-1.29) 5.4x10
-1
 2.9x10
-2
 1.1x10
-2
 85 
rs6927322 6 T/G 0.04 1.55 (1.27-1.89) 1.2x10
-5
 - - 1.24 (1.08-1.43) 3.2x10
-3
 6.1x10
-6
 1.1x10
-1
 61 
rs13279707 8 T/C 0.05 1.58 (1.29-1.92) 7.5x10
-6
 1.28 (1.06-1.56) 1.1x10
-2
 1.06 (0.92-1.22) 4.2x10
-1
 2.7x10
-3
 1.0x10
-4
 89 
rs7107174 11 T/C 0.15 1.14 (1.01-1.30) 4.2x10
-2
 1.21 (1.07-1.36) 2.0x10
-3
 1.26 (1.16-1.37) 4.8x10
-8
 9.7x10
-11
 4.6x10
-1
 0 
rs4561483 16 A/G 0.35 1.22 (1.10-1.35) 1.3x10
-4
 1.20 (1.10-1.32) 1.1x10
-4
 1.09 (1.02-1.16) 8.1x10
-3
 1.6x10
-8
 9.7x10
-2
 57 
rs3850997 16 T/G 0.33 1.17 (1.06-1.30) 2.5x10
-3
 1.18 (1.07-1.30) 7.6x10
-4
 1.06 (1.00-1.13) 6.9x10
-2
 1.0x10
-5
 1.2x10
-1
 54 
rs55637647 16 G/C 0.37 1.21 (1.10-1.34) 6.5x10
-5
 - - 1.17 (1.09-1.24) 2.7x10
-6
 3.4x10
-9
 5.2x10
-1
 0 
 
1
 dbSNP rs number 
2
 Alleles (Risk Allele is underlined) 
3
 Risk Allele Frequency 
4
 
 
OR: per allele odds ratio 
5 
Ptrend: P-value for trend, via logistic regression 
6 
Pmeta: P-value for fixed effects meta-analysis  
7
 Phet: P-value of heterogeneity between studies  
8
 I
2
 heterogeneity index (0-100) 
 
Table 1 - Summary of results across all genotyping stages. SNPs highlighted in bold achieved genome wide 
significance. 
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